title: High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre.
abstract: The aim of this study was to investigate the efficacy of riboflavin for the prevention of migraine. An open label study was performed in a specialized outpatient clinic. Patients received 400 mg riboflavin capsules per day. Headache frequency, duration, intensity and the use of abortive drugs were recorded at baseline and 3 and 6 months after treatment. Headache frequency was significantly reduced from 4 days/month at baseline to 2 days/month after 3 and 6 months (P < 0.05). The use of abortive drugs decreased from 7 units/month to 4.5 units/month after 3 and 6 months of treatment (P < 0.05). In contrast, headache hours and headache intensity did not change significantly. We could demonstrate a significant reduction of headache frequency following riboflavin treatment. In addition, the number of abortive anti-migraine tablets was reduced. In line with previous studies our findings show that riboflavin is a safe and well-tolerated alternative in migraine prophylaxis.
authors.affiliation: Department of Neurology, Charité, Humboldt University of Berlin, Berlin, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Boehnke
authors.forename: U
authors.initials: U
authors.lastname: Reuter
authors.forename: U
authors.initials: U
authors.lastname: Flach
authors.forename: S
authors.initials: S
authors.lastname: Schuh-Hofer
authors.forename: K M
authors.initials: KM
authors.lastname: Einhäupl
authors.forename: G
authors.initials: G
authors.lastname: Arnold
mesh_terms: D000328:Adult; D000368:Aged; D000554:Ambulatory Care Facilities; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000517:prevention & control*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D012256:Riboflavin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D017319:Photosensitizing Agents; D012256:Riboflavin